- Intelligencia AI specializes in software development that leverages artificial intelligence to de-risk drug development, aiming to enhance decision-making in the pharmaceutical industry.
- In August 2021, the company secured $15.5 million in total funding, including a Series A round, and was recognized on the Inc. 5000 list for the second consecutive year, ranking No. 2454 in 2025 with a three-year revenue growth of 173%.
- The company collaborates with several major global pharmaceutical companies and mid-size biotechnology firms, providing AI-driven solutions that improve the probability of success in clinical trials.
- Intelligencia AI's ideal buyers are pharmaceutical and biotechnology companies seeking to reduce the risks and costs associated with drug development, making their AI solutions particularly relevant in today's high-stakes healthcare landscape.
Intelligencia AI comprises six departments, with the largest being Community and Social Services, which employs 19 individuals. Information Technology follows with a headcount of 9, while Operations contributes 4 employees. This distribution indicates a strong focus on community engagement and technical support, with a balanced approach to operational needs and executive leadership, which consists of 3 members.
The company operates from two primary locations, with a notable concentration of employees categorized under 'Other,' totaling 43 individuals. Additionally, there is one employee each in New Haven, CT, and San Francisco, CA. This distribution suggests a predominantly remote workforce, reflecting a flexible operational model that supports geographic diversity while maintaining a centralized presence in key urban areas.
